Q-omics provides the consensus-scored RPL12P14 profile across patient tissues and cancer cell-line models. RPL12P14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, RPL12P14 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, RPL12P14 RNA expression shows 10,417 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, COAD, and TGCT as cancer lineages where RPL12P14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL12P14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL12P14 survival associations across molecular data types. RPL12P14 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL12P14 RNA expression–survival associations across cancer types. High RPL12P14 expression shows unfavorable associations in LUAD, LGG, KICH and BLCA, but favorable associations in KIRC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for RPL12P14 RNA expression.
This table summarizes RPL12P14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL12P14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL12P14 shows lower tumor expression in COAD, KICH and KIRP and higher tumor expression in HNSC, LIHC and THCA. The COAD box plot shows higher RPL12P14 RNA expression in normal versus tumor tissue (log2 FC = −2.682, t-test p < 0.001).
This table shows molecular features associated with RPL12P14 in patient tissues and cancer cell lines. In patient samples, RPL12P14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
